Samsung Bioepis Builds Its Biosimilars Name In Europe
Executive Summary
EU clearance of Samsung Bioepis' Imraldi, its adalimumab biosimilar, is the South Korean firm's third biosimilar anti-TNF alpha product to get approval in Europe.
You may also be interested in...
End In Sight: Humira Stacks Up 20 Years Of US Market Exclusivity
AbbVie, for the second time, has resolved a Humira patent dispute that protects the drug's US commercial exclusivity until 2023. The latest deal with Samsung Biopesis follows a similar agreement with Amgen, giving Amgen a five-month head start with its biosimilar.
End In Sight: Humira Stacks Up 20 Years Of US Market Exclusivity
AbbVie, for the second time, has resolved a Humira patent dispute that protects the drug's US commercial exclusivity until 2023. The latest deal with Samsung Biopesis follows a similar agreement with Amgen, giving Amgen a five-month head start with its biosimilar.
Samsung's Ontruzant Becomes First Trastuzumab Biosimilar Approved In EU
Samsung Bioepis is poised to grab the leading position in the trastuzumab biosimilar market in Europe as its biosimilar Ontruzant gets the European Commission's approval ahead of the competition.